So far, we’ve raised $600K.
We got combination gene therapy into the clinic.
With $1M, we can do the same for both: gene-therapy-based partial reprogramming and partial chemical reprogramming — the latter potentially being a safer option.
It’s cool that the field has so much funding.
I have nothing against partial reprogramming. But what if it doesn’t work? We could waste billions and a couple of decades on one hypothesis, and end up with nothing but investors disappointed in the field — the same thing that happened with antioxidants, senolytics, telomeres…
If the goal is not just to make a lot of money on the next IPO, but to really solve the problem while the people we love are still alive, we should test multiple hypotheses and their combinations simultaneously — quickly and cheaply.
Vasculature restoration with VEGF plasmid gene therapy in a CLI stage IIb patient.
Before and 6 months after.
2 sessions of 20+ i/m injections in each leg.
#vegf#pad#CriticalLimbIschemia
Unlimited Bio was fully blown away by Vitalist Bay 2026. 4 days packed with exceptional people united with a common mission and an incredible wrap up with Peter Diamandis.
Kudos to Adam, vitalism team, amazing volunteers and all the vitalists for making it happen!
Peter Diamandis at Vitalist Bay: “I’m interested in follistatin and Klotho.”
Good news: both follistatin and Klotho gene therapies are part of Unlimited Bio’s XPRIZE final protocol.
1. The CALM-AF-AI trial is not designed to make the participants look extremely muscular. We start with a milder dose and mostly expect a local effect in the injected muscles (arms and legs).
2. Most of these animals have myostatin, often described as a “muscle brake,” completely switched off.
3. Our aim is to upregulate follistatin, which may downregulate myostatin and potentially lead to increased muscle mass.
4. This is a safety trial, so risks do exist. We are well aware of the risks associated with AAV gene delivery, and we have designed a multi-layered system to protect participants.
5. The trial has been approved by the GARM International Foundation IRB and Próspera Insurance Company. It is conducted in accordance with Próspera Health Services Regulation A, within a licensed medical facility. Participants are required to sign a comprehensive informed consent form before enrolling.
6. Please contact us through the official channels listed on our website for the information regarding this trial.
I'm proud to announce a trial!
And YOU -- yes, you! -- might be able to get in it.
At the end of this thread, you'll find a link to sign up.
The trial is for a gene therapy for HUGE MUSCLES🧵 (like this cow)
If you happen to meet investors obsessed with lifespan extension, please send them our way. Thank you.
If you happen to meet investors obsessed with healthspan extension, please send them our way as well. Thanks again.
Why is there such obsession with extending lifespan when the bigger issue is that average healthspan is 65 years and there are no data (except in super-centenarians) that longer lifespan = longer healthspan (known as compression of morbidity)?
We’re excited to share that Unlimited Bio’s AAV-Follistatin gene therapy has been successfully manufactured and is now in the clinical site for the CALM-AF-AI trial at Prospera.
This marks the first AAV-based gene therapy on Prospera’s territory — an important step toward bringing advanced genetic medicine to new frontiers!
Unlimited Bio has opened recruitment for CALM-AF-AI, a Phase 1/2a clinical trial evaluating the safety of AAV9-Follistatin alone and in combination with VEGF plasmid gene therapy for age-related muscle decline.
GARM in Roatan is the designated CALM-AF-AI study site where eligible participants will complete in-person study visits and protocol-required procedures under clinical supervision.